Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of neural transmission

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF01277665PMID 9295179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of chelators on iron uptake and release by the brain in the rat

  2004cited by this paper
• Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the two metals.

  1996cited by this paper
• Desferrioxamine inhibition of the hydroxyl radical-like reactivity of peroxynitrite: role of the hydroxamic groups.

  1995cited by this paper
• Relationship between free iron level and rat liver mitochondrial dysfunction in experimental dietary iron overload.

  1995cited by this paper
• Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism.

  1995influential reference
• Hepatic mitochondrial oxidative metabolism and lipid peroxidation in iron-loaded rats fed ethanol.

  1995cited by this paper
• Effects of deferoxamine and a diet deficient in vitamin E on isoelectric electroencephalographic responses associated with ischemia by the four vessel occlusion method.

  1995cited by this paper
• A new animal model of cerebral infarction: magnetic embolization with carbonyl iron particles.

  1995cited by this paper
• Experimental liver cirrhosis induced by alcohol and iron.

  1995cited by this paper
• Oxidative stress: Free radical production in neural degeneration

  1994cited by this paper
• Intranigral Iron Infusion as a Model for Parkinson’s Disease

  1994cited by this paper
• Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.

  1994cited by this paper
• Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?

  1994cited by this paper
• Oxidative stress: free radical production in neural degeneration.

  1994cited by this paper
• Nigral dopaminergic cell loss in vitamin E deficient rats.

  1994cited by this paper
• Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain

  1994cited by this paper
• Oxidation of desferrioxamine to nitroxide free radical by activated human neutrophils.

  1993cited by this paper
• The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.

  1993cited by this paper
• The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury. Reversal by tirilazad mesylate (U-74006F).

  1993cited by this paper
• Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

  1993cited by this paper
• Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers

  1993cited by this paper
• Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease

  1993cited by this paper
• Role of iron and iron chelation in dopaminergic‐induced neurodegeneration: Implication for Parkinson's disease

  1992cited by this paper
• A pilot trial of high‐dose alpha‐tocopherol and ascorbate in early Parkinson's disease

  1992cited by this paper
• Iron induces degeneration of nigrostriatal neurons.

  1992cited by this paper
• Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains

  1991cited by this paper
• Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats

  1991cited by this paper
• The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons

  1991cited by this paper
• Developmental changes in transferrin and iron uptake by the brain in the rat.

  1990cited by this paper
• Vitamin E in biological systems.

  1990cited by this paper
• Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.

  1990cited by this paper
• Current status of iron chelation therapy with deferoxamine.

  1990cited by this paper
• Desferrioxamine as a lipid chain‐breaking antioxidant in sickle erythrocyte membranes

  1990cited by this paper
• MPTP toxicity in the mouse brain and vitamin E.

  1990cited by this paper
• Prevention of hepatocyte injury and lipid peroxidation by iron chelators and α‐tocopherol in isolated iron‐loaded rat hepatocytes

  1990cited by this paper
• A method for the comparative assessment of antioxidants as peroxyl radical scavengers.

  1989cited by this paper
• Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

  1989cited by this paper
• Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence.

  1989cited by this paper
• Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

  1989cited by this paper
• Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains

  1989cited by this paper
• Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action?

  1989cited by this paper
• Protective effect of the iron chelator deferoxamine on cold-induced brain edema.

  1989cited by this paper
• Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

  1989cited by this paper
• DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

  1989cited by this paper
• Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.

  1989cited by this paper
• Effect of deprenyl on the progression of disability in early Parkinson's disease.

  1989cited by this paper
• Effect of High Doses of Dietary Vitamin E on the Concentrations of Vitamin E in Several Brain Regions, Plasma, Liver, and Adipose Tissue of Rats

  1988cited by this paper
• Oxidants and human disease: some new concepts

  1987cited by this paper
• Effects of Methylprednisolone and the Combination of α‐Tocopherol and Selenium on Arachidonic Acid Metabolism and Lipid Peroxidation in Traumatized Spinal Cord Tissue

  1987cited by this paper
• Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography. Differential effect of probenecid, haloperidol and yohimbine on the concentrations of biogenic amines and metabolites in various

  1987cited by this paper
• Oxidants and human disease: some new concepts 1

  1987cited by this paper
• Development of new cerebral protective agents: the free radical scavengers.

  1986cited by this paper
• Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts.

  1986cited by this paper
• Ischemia, resuscitation, and reperfusion: mechanisms of tissue injury and prospects for protection.

  1986cited by this paper
• Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

  1985cited by this paper
• Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse.

  1985cited by this paper
• Formation of alpha-tocopherol complexes with fatty acids. A hypothetical mechanism of stabilization of biomembranes by vitamin E.

  1984cited by this paper
• Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products.

  1984cited by this paper
• Oxygen toxicity, oxygen radicals, transition metals and disease.

  1984cited by this paper
• Desferrioxamine: a scavenger of superoxide radicals?

  1984cited by this paper
• [Formation of alpha-tocopherol complexes with fatty acids. Possible mechanism of biomembrane stabilization by vitamin E].

  1983cited by this paper
• Glutathione and Ascorbate During Ischemia and Postischemic Reperfusion in Rat Brain

  1980cited by this paper
• Determination of malonaldehyde precursor in tissues by thiobarbituric acid test.

  1978cited by this paper
• Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues.

  1969cited by this paper
• The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism

  1964cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Deferoxamine halt rotenone-induced Parkinson’s like symptoms in experimental rats: biochemical, neuroinflammatory, neurotransmitters, and histological evidence

  2025cites this paper
• Oxidative Stress and Nutritional Antioxidants in Neurological Diseases

  2025cites this paper
• Oxidative Stress and Neurodegeneration: Insights and Therapeutic Strategies for Parkinson’s Disease

  2024cites this paper
• Driving factors of neuronal ferroptosis.

  2024cites this paper
• Oxidative Stress and Antioxidants in Neurodegenerative Disorders

  2023cites this paper
• The Effects of a High Concentration of Dissolved Oxygen on Actinobacteria from Lake Baikal

  2023cites this paper
• Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine

  2022cites this paper
• Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review

  2022cites this paper
• Tailoring a luminescent metal − organic framework precise inclusion of Pt-Aptamer nanoparticle for noninvasive monitoring Parkinson's disease

  2022cites this paper
• Healthy dietary intake moderates the effects of age on brain iron concentration and working memory performance.

  2021cites this paper
• The Effects of Redox-Active Metal Ions and Amyloid-Degrading Enzymes on the Pathology of Alzheimer's Disease

  2021cites this paper
• Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease

  2021cites this paper
• The assessment of possible gender-related effect of endogenous striatal alpha-tocopherol level on MPTP neurotoxicity in mice

  2020cites this paper
• Potential Role of Tocotrienols on Non-Communicable Diseases: A Review of Current Evidence

  2020cites this paper
• Recent insight on improving the iron chelation efficacy of deferasirox by adjuvant therapy in transfusion dependent beta thalassemia children with sluggish response

  2020cites this paper
• Autophagy and Redox Homeostasis in Parkinson's: A Crucial Balancing Act

  2020cites this paper
• Overdosing on iron: Elevated iron and degenerative brain disorders

  2020cites this paper
• The Role of Oxidative Stress in Parkinson’s Disease

  2020cites this paper
• Iron Pathophysiology in Parkinson Diseases.

  2019cites this paper
• Streptomyces monashensis sp. nov., a novel mangrove soil actinobacterium from East Malaysia with antioxidative potential

  2019cites this paper
• The potential application of rapeseed pomace extracts in the prevention and treatment of neurodegenerative diseases

  2019cites this paper
• Neuroprotective effect of phytic acid in Parkinson ' s disease

  2018cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review).

  2018cites this paper
• The role of oxidative stress in anxiety disorder: cause or consequence?

  2018cites this paper
• Physiological Effects of Nutritional Support in Patients with Parkinson ’ s Disease

  2018cites this paper
• Mitochondria-mediated damage to dopaminergic neurons in Parkinson's disease (Review).

  2017cites this paper
• The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

  2017cites this paper
• Nutrition and Disease Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease

  2017cites this paper
• Advances in the Chemical Biology of Desferrioxamine B.

  2017cites this paper
• Glutathione, Glutaredoxins, and Iron

  2017cites this paper
• Gut microbiota: Implications in Parkinson's disease

  2017cites this paper
• Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease.

  2017cites this paper
• Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease.

  2017cites this paper
• Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View

  2016cites this paper
• Mechanisms of divalent metal toxicity in affective disorders.

  2016cites this paper
• NEUROTOXICOLOGICAL EVALUATION OF PLUMBAGO ZEYLANICA L. ROOT EXTRACT AND AMELIORATIVE EFFECT OF VITAMIN.E IN AN EXPERIMENTAL MICE

  2016cites this paper
• The effects of exposure to the environmental neurotoxicant manganese on α-synuclein and its cell-to-cell transmission via exosomes

  2016cites this paper
• Damage to dopaminergic neurons is mediated by proliferating cell nuclear antigen through the p53 pathway under conditions of oxidative stress in a cell model of Parkinson's disease.

  2016cites this paper
• Mitochondrial Therapeutic Approaches in Parkinson’s Disease

  2016cites this paper
• Antioxidants and Redox-Based Therapeutics in Parkinson’s Disease

  2016cites this paper
• Streptomyces malaysiense sp. nov.: A novel Malaysian mangrove soil actinobacterium with antioxidative activity and cytotoxic potential against human cancer cell lines

  2016cites this paper
• TRPM7 function in zebrafish dopaminergic neurons

  2015cites this paper
• Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration.

  2015cites this paper
• Metal Exposure and Oxidative Stress Induced Parkinson’s Disease

  2015cites this paper
• Nigral Iron Elevation Is an Invariable Feature of Parkinson's Disease and Is a Sufficient Cause of Neurodegeneration

  2014cites this paper
• The emerging role of nutrition in Parkinson's disease

  2014cites this paper
• MRI assessment of brain iron content in methamphetamine users

  2014influential citation
• Systemic Redox Biomarkers in Neurodegenerative Diseases.

  2014cites this paper
• Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.

  2014cites this paper
• Abnormal differentiation of dopaminergic neurons in zebrafish trpm7 mutant larvae impairs development of the motor pattern.

  2014cites this paper
• Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.

  2014cites this paper
• Advances in non-dopaminergic treatments for Parkinson's disease

  2014cites this paper
• The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease

  2014cites this paper
• Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.

  2013cites this paper
• Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

  2013cites this paper
• Genetics and iron in the systems biology of Parkinson's disease and some related disorders.

  2013cites this paper
• Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats.

  2013cites this paper
• Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression.

  2013cites this paper
• The Role of Oxidative Stress in Parkinson's Disease

  2013cites this paper
• Neurobiology of Parkinson's Disease Gene Pink1 in Danio rerio (Zebrafish)

  2013cites this paper
• Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.

  2013cites this paper
• Carnosic acid dietary supplementation at 0.12% rates slows down meat discoloration in gluteus medius of fattening lambs.

  2012cites this paper
• Central nervous system damage due to acute paraquat poisoning: a neuroimaging study with 3.0 T MRI.

  2012cites this paper
• Chelators in the Treatment of Iron Accumulation in Parkinson's Disease

  2012cites this paper
• Green Tea Flavan-3-ols and Their Role in Protecting against Alzheimer’s and Parkinson’s Disease Pathophysiology

  2012cites this paper
• Antioxidants included in the diet of fattening lambs: Effects on immune response, stress, welfare and distal gut microbiota

  2012cites this paper
• Role of the prolyl isomerase Pin1 in the pathogenesis of Parkinson's disease and neuroprotection by novel targeted compounds in pre-clinical animal models of the disease

  2012cites this paper
• The Role of Free Radicals in the Aging Brain and Parkinson’s Disease: Convergence and Parallelism

  2012cites this paper
• METALLOTHIONEINS AS EARLY AND SENSITIVE BIOMARKERS OF REDOX SIGNALING IN NEURODEGENERATIVE DISORDERS

  2011cites this paper
• The Promise of Neuroprotective Agents in Parkinson’s Disease

  2011influential citation
• Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.

  2011cites this paper
• Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

  2011cites this paper
• Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection

  2011cites this paper
• Mapping Brain Metals to Evaluate Therapies for Neurodegenerative Disease

  2011cites this paper
• The chemical process of oxidative stress by copper(II) and iron(III) ions in several neurodegenerative disorders

  2011cites this paper
• Monoamine oxidase (MAO) activity and MAO-derived hydroxyl radical production in mouse model of hepatic ischemia-reperfusion injury (Fare modeli karaciğer iskemi-reperfüzyon hasarinda monoamin oksidaz (MAO) aktivitesi ve MAO kaynakli hidroksil radikali üretimi)

  2011cites this paper
• Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities

  2010influential citation
• Manganese chelation therapy extends survival in a mouse model of M1000 prion disease

  2010cites this paper
• Hypoxia‐inducible factor 1: a new hope to counteract neurodegeneration?

  2010cites this paper
• Oxygen sensing: a common crossroad in cancer and neurodegeneration.

  2010cites this paper
• Chelation therapy for neurodegenerative diseases

  2009cites this paper
• Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson’s disease

  2009cites this paper
• Molecular pathways related to neuronal cell death and suggested oxidising properties of iron via a Fenton reaction

  2009cites this paper
• Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30

  2009cites this paper
• Neurobehavioural deficits following postnatal iron overload: II instrumental learning performance

  2009cites this paper
• Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity

  2009cites this paper
• Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential?

  2009cites this paper
• Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

  2009cites this paper
• Iron and Monoamine Oxidase in Brain Function and Dysfunction: Development of Neuroprotective-Neurorescue Drugs

  2009cites this paper
• Interaction of psychostimulant intake with brain aging: Effects on behavioral capacity, oxidative damage and dopaminergic markers

  2009cites this paper
• Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease

  2009cites this paper
• A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.

  2008cites this paper
• Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra.

  2008cites this paper
• Reversion of age-related recognition memory impairment by iron chelation in rats.

  2008cites this paper
• Redox imbalance in Parkinson's disease.

  2008cites this paper
• Influence of H102 on the expression of amyloid protein and amyloid precursor protein in the hippocampus of APP 695 transgenic mice

  2008cites this paper
• Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

  2008cites this paper
• Iron chelation attenuates intracranial pressure and improves survival in a swine model of acute liver failure

  2008cites this paper
• Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease.

  2008cites this paper